Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer
暂无分享,去创建一个
C. Hudis | L. Norton | M. Theodoulou | T. Traina | L. Tan | S. Patil | K. Feigin | D. Gajria | S. Geneus
[1] E. Perez,et al. Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC). , 2009 .
[2] E. Perez,et al. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. , 2009 .
[3] N. Harbeck,et al. Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC). , 2009 .
[4] D. Lake,et al. Phase II Evaluation of a Novel Capecitabine Schedule in Combination with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab. , 2009 .
[5] S. Loibl,et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] N. Harbeck,et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. , 2008 .
[7] E. Van Cutsem,et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Larry Norton,et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[10] H. Gómez,et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Gradishar,et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer , 2007 .
[12] M. Stockler,et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC) , 2007 .
[13] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[14] J. O’Shaughnessy,et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] G. Cervantes,et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Jemal,et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival , 2004, Cancer.
[18] S. Culine,et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. , 2004, European journal of cancer.
[19] A. Schindler,et al. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] W. Scheithauer,et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] David Miles,et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Buzdar,et al. Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients , 2001, Cancer.
[23] H. Burger,et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] R. Sorelle. US Department of Health and Human Services gives states wider latitude in choosing services to be covered by Medicaid. , 2001, Circulation.
[25] A. Buzdar,et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] B. Reigner,et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Ratain. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Brian Higgins,et al. Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. , 2010, Breast disease.
[29] K. Syrigos,et al. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.